Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics
|
Glucose-6-phosphate dehydrogenase deficiency Microchapters |
|
Differentiating Glucose-6-phosphate dehydrogenase deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics |
|
FDA on Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics |
|
CDC on Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics |
|
Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics in the news |
|
Blogs on Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics |
|
Directions to Hospitals Treating Glucose-6-phosphate dehydrogenase deficiency |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahda Alihashemi M.D. [2]
Overview
Epidemiology and Demographics
Incidence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
Prevalence
- G6PD deficiency is affecting 400 million people worldwide. [1]
Case-fatality rate/Mortality rate
- G6PD deficiency resulted in 4,100 deaths in 2013 and 3,400 deaths in 1990[2]
Age
- Patients of all age groups may develop favism (acute hemolytic anemia from eating fava beans ) but more often and severe in childern
Race
- African, Middle Eastern and South Asian people are affected the most.
Gender
- Men are more commonly affected by G6PD deficiency than women, because it is an X-linked recessive disorder.
Region
- The majority of G6PD deficiency cases are reported in African, Middle Eastern and South Asian people. [3]
References
- ↑ Mason PJ, Bautista JM, Gilsanz F (September 2007). "G6PD deficiency: the genotype-phenotype association". Blood Rev. 21 (5): 267–83. doi:10.1016/j.blre.2007.05.002. PMID 17611006.
- ↑ "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013". Lancet. 385 (9963): 117–71. January 2015. doi:10.1016/S0140-6736(14)61682-2. PMC 4340604. PMID 25530442.
- ↑ Beutler E (January 1991). "Glucose-6-phosphate dehydrogenase deficiency". N. Engl. J. Med. 324 (3): 169–74. doi:10.1056/NEJM199101173240306. PMID 1984194.
|
Glucose-6-phosphate dehydrogenase deficiency Microchapters |
|
Differentiating Glucose-6-phosphate dehydrogenase deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics |
|
FDA on Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics |
|
CDC on Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics |
|
Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics in the news |
|
Blogs on Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics |
|
Directions to Hospitals Treating Glucose-6-phosphate dehydrogenase deficiency |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.D. [4]
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Epidemiology and Demographics
- G6PDD is said to be the most common enzyme deficiency disease in the world, affecting approximately 400,000,000 people globally.[1]
- A side effect of this disease is that it confers protection against malaria, in particular the form of malaria caused by Plasmodium falciparum, the most deadly form of malaria.
- A similar relationship exists between malaria and sickle-cell disease. An explanation is that cells infected with the Plasmodium parasite are cleared more rapidly by the spleen. This phenomenon might give G6PD deficiency carriers an evolutionary advantage.